logo-loader
viewHumanigen, Inc.

Humanigen inks licensing agreement with the University of Zurich to strengthen its treatment of graft-versus-host disease in leukemia patients

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based company has a new tool in its box to prevent graft-versus-host disease when treating patients with leukemia and other blood cancers.

Durrant says Humanigen has received an exclusive licensing agreement from the University of Zurich in Switzerland to utilize its GM-CSF protein neutralization technology, shown to mitigate graft-versus-host without stifling the positive effects of leukemia treatment.

Quick facts: Humanigen, Inc.

Price: 0.39 USD

OTCQB:HGEN
Market: OTCQB
Market Cap: $46.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: ADM Energy CEO to use strong local knowledge to land deals

ADM Energy (LON:ADME) CEO Osamede Okhomina grew up in the UK but knows Nigeria inside out. "It's about knowing how to deal with each tribal culture and getting the best from each negotiation.." says Cambridge-educated Okhomina. ADME is a natural resources investment company but Okhomina would...

5 hours, 45 minutes ago

2 min read